- Home
- AZ vs IKT Comparison
AZ vs IKT Comparison
Compare AZ & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | IKT |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 201.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZ | IKT |
|---|---|---|
| Price | $5.44 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $5.50 |
| AVG Volume (30 Days) | 405.2K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.87 | N/A |
| Revenue Next Year | $480.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $1.33 |
| 52 Week High | $12.36 | $2.58 |
Technical Indicators
Market Signals| Indicator | AZ | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 53.98 |
| Support Level | $5.10 | $1.45 |
| Resistance Level | $6.63 | $2.14 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 36.27 | 39.34 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.